At present, "foreign Chinese medicine" has aggressively attacked the Chinese market. The annual sales of the world botanical drug market exceeds 16 billion US dollars, and is increasing at a rate of 10% to 20% per year. Recently, the global top OTC pharmaceutical companies ranked the top 100 German Dr. Ma. In May last year, a large pharmaceutical factory officially rushed to China with a botanical drug that detoxifies and nourishes constipation. In June 2004, Professor Fered Murad, the Nobel laureate of the "Father of Viagra", was awarded The magical Chinese herbal medicine is deeply attracted and came to China for entrepreneurship. The Murad Traditional Chinese Medicine Modernization Research Center, which was established in cooperation with Shanghai University of Traditional Chinese Medicine, was established in 2004. On November 2, 2004, Novartis Pharmaceuticals of Switzerland and Shanghai Institute of Chinese Medicine The Pharmaceutical Research Institute renewed the cooperation agreement, adding another US$1.5 million to the first phase of the cooperation to inject US$2 million, and continued to strengthen cooperation with Shanghai Pharmaceuticals in the research of natural compounds and new drugs; international pharmaceutical giants implemented joint ventures and investments in China. Localization strategies have poured into the Chinese natural plant medicine market... Industry insiders predict that in the next five years, this entry speed will deliver VUIR at a rate of 300% per year. Traditional Chinese medicine has triggered a "world war" in the medical field.
According to a survey report, developed countries have spent an average of 15% on the development of plant medicines in the past 10 years. Among them, 15 of the world's largest pharmaceutical companies in the world have increased their research expenditure by 22.5% annually. When developed countries develop botanical medicines in a big way, the third world with numerous plant and medicine resources is suddenly waking up. Although there are more than 1,000 Chinese medicine companies in China, there are still too few enterprises that are on the scale and meet international production standards. Because it is impossible to guarantee comprehensive quality control of Chinese medicine production from the aspects of source and production, there is no quantitative standard for pharmacology and composition. Zhongxin Pharmaceutical (600329) is the main product of the quick-acting rescue heart pills for 20 years. The recently developed capsules have been confirmed by the research group of the Chinese Ministry of Science and Technology's basic research project "Chinese herbal medicine standards and clinical efficacy observation standards for related Chinese medicines". As the only clinical experimental drug for rheumatic diseases, it has become a banner for modern Chinese medicine in pharmacological research and development.
Recently, the capsules developed and produced by Tianjin Darentangda Pharmaceutical Co., Ltd., a subsidiary of Sino-Singapore Pharmaceuticals Co., Ltd., have just been identified as the only rheumatism by the research group of the Chinese Ministry of Science and Technology's basic research project "Chinese herbal medicine standards and relevant clinical medicine clinical efficacy observation standards". Clinical trial drugs for diseases. The capsule prescription is derived from the "One Grain Xiandan" of the famous doctor of Huadai in the Han Dynasty. It is developed by the Chinese Medicine Pharmaceutical Group Tianjin Darentangda Pharmaceutical Co., Ltd. using modern pharmaceutical technology and researched through nearly ten years of research. * Three new drugs. The quick-acting rescue heart pills are China's large-scale production of traditional Chinese medicine dropping pills. It is one of the only three secret Chinese patent medicines with independent intellectual property rights in China. Its formula and process are all within the scope of confidentiality. After 22 years of extensive clinical use, the superb performance of the quick-acting rescue heart pills has convinced domestic and foreign cardiovascular experts. As a drug with modern Chinese medicine characteristics, it not only has the first-aid effect that is not available in general cardiovascular Chinese medicines. And in terms of treatment, there are outstanding features in terms of composition, mechanism of action, clinical efficacy and applicable population. Its export share is close to 30%, which is recognized by the Western market.
HEBEI PINGLE FLOUR MACHINERY GROUP CO., LTD , https://www.plrollermill.com